Nurix Therapeutics, Inc. (NRIX) Tops Q3 EPS by 16c

Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q3 EPS of ($0.68), $0.16 better than the analyst estimate of ($0.84). Revenue for the quarter came in at $18.47 million versus the consensus estimate of $11.94 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• CVG to join Russell 2000 and Russell 3000 indexes June 26